At the news
? BULLISHIMPACT 7/10 COURT-RULING filed Jul 8, 2026 at 20:00 ET
The Federal Circuit affirmed the district court's grant of JMOL of invalidity for lack of enablement of Wyeth's asserted patents (U.S. Patent 10,603,314 and 10,596,162) covering methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors. The ruling permanently removes the patent infringement risk to AstraZeneca's Tagrisso (osimertinib) and vacates the $107.5M jury verdict against AstraZeneca, eliminating a material liability and IP overhang.
- Federal Circuit affirmed district court's JMOL of invalidity for lack of enablement of Wyeth's asserted claims in U.S. Patents 10,603,314 and 10,596,162
- The ruling vacates the $107,500,000 jury verdict against AstraZeneca for induced infringement of Tagrisso (osimertinib)
- The patents claimed methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors; the court found the specification failed to enable a daily unit dosage for human patients without undue experimentation
- The Federal Circuit affirmed that the specification provided no working examples of unit dosages in patients and disclosed dosage ranges that were toxic for at least two of the three preferred compounds
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access